Hans Van Vlierberghe
Overview
Explore the profile of Hans Van Vlierberghe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
226
Citations
4971
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heyerick L, Dhondt A, Van Vlierberghe H, Verhelst X, Raevens S, Geerts A
World J Hepatol
. 2025 Mar;
17(2):102375.
PMID: 40027565
Background: Benign recurrent intrahepatic cholestasis (BRIC) is a rare autosomal recessive liver disease, causing episodic cholestasis with intense pruritus. This case report highlights the effectiveness of early plasmapheresis as a...
2.
Voet F, Khalenkow M, De Pauw M, Verhelst X, Lefere S, Geerts A, et al.
Ann Hepatol
. 2025 Feb;
30(2):101784.
PMID: 39947466
Introduction And Objectives: Cirrhotic cardiomyopathy (CCM) is a cardiac complication of cirrhosis primarily presenting as diastolic dysfunction (DD). The original diagnostic criteria from 2005 were updated in 2019. This retrospective...
3.
Furquim dAlmeida A, Ho E, Govaerts L, Michielsen P, Serste T, Bourgeois S, et al.
J Viral Hepat
. 2025 Jan;
32(2):1-15.
PMID: 39846497
Hepatitis B virus (HBV)-hepatitis delta virus (HDV) coinfection is the most severe form of chronic viral hepatitis, but the factors that determine disease progression and severity are incompletely characterised. This...
4.
Heldens A, Casteleyn C, Onghena L, Antwi M, Neyt S, Descamps B, et al.
Biomed Pharmacother
. 2025 Jan;
183:117826.
PMID: 39805191
Portal hypertension (PH) can cause severe complications in patients with advanced chronic liver disease (aCLD). The pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist lanifibranor reduces portal pressure in preclinical models of aCLD....
5.
Onghena L, van Nieuwenhove Y, Van Vlierberghe H, Devisscher L, Raevens S, Verhelst X, et al.
United European Gastroenterol J
. 2024 Nov;
12(10):1440-1449.
PMID: 39545623
Background: Patients with a history of metabolic and bariatric surgery (MBS) are susceptible to developing alcohol use disorder, potentially resulting in end-stage liver disease, with a paucity of data on...
6.
Somers N, Butaye E, Grossar L, Pauwels N, Geerts A, Raevens S, et al.
Oncol Lett
. 2024 Nov;
29(1):24.
PMID: 39530005
Hepatocellular carcinoma (HCC) is one of the most lethal malignancies, which is associated with a low 5-year survival rate. The importance of effective disease monitoring and prognostic evaluation is undeniable....
7.
Buytaert M, Declercq D, Depoorter F, Cosijn Z, Devisscher L, Raevens S, et al.
Pediatr Obes
. 2024 Sep;
:e13174.
PMID: 39340247
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a major public health concern. A thorough analysis of the link between ultra-processed food (UPF) intake and MASLD in the adolescent...
8.
Benoit D, De Pauw A, Jacobs C, Moors I, Offner F, Velghe A, et al.
Intensive Care Med
. 2024 Sep;
51(1):245-246.
PMID: 39297947
No abstract available.
9.
Grossar L, Raevens S, Van Steenkiste C, Colle I, De Vloo C, Orlent H, et al.
JHEP Rep
. 2024 Sep;
6(9):101149.
PMID: 39247177
Background & Aims: The goal of treatment in autoimmune hepatitis (AIH) is induction of remission to prevent the development of liver fibrosis, cirrhosis, and its related complications. Various definitions of...
10.
Benoit D, De Pauw A, Jacobs C, Moors I, Offner F, Velghe A, et al.
Intensive Care Med
. 2024 Sep;
50(10):1635-1646.
PMID: 39230678
Purpose: The aim of this study was to assess whether coaching doctors to enhance ethical decision-making in teams improves (1) goal-oriented care operationalized via written do-not-intubate and do-not attempt cardiopulmonary...